{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:36:18Z","timestamp":1787063778257,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals USA Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"DFG","doi-asserted-by":"publisher","award":["SCHM 3018 \/ 4-1"],"award-info":[{"award-number":["SCHM 3018 \/ 4-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jbc.2024.105784","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T05:56:10Z","timestamp":1708667770000},"page":"105784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Triple-fusion protein (TriFu): A potent, targeted, enzyme-like inhibitor of all three complement activation pathways"],"prefix":"10.1016","volume":"300","author":[{"given":"Sophia J.","family":"Sonnentag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Dopler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Kleiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brijesh K.","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Mannes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Sp\u00e4th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Akilah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"H\u00f6chsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Schrezenmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Anliker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby","family":"Boyanapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Huber-Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph Q.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2024.105784_bib1","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jbc.2024.105784_bib2","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jbc.2024.105784_bib3","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jbc.2024.105784_bib4","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jbc.2024.105784_bib5","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"133","author":"Lee","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jbc.2024.105784_bib6","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","article-title":"Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study","volume":"133","author":"Kulasekararaj","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jbc.2024.105784_bib7","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","article-title":"Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"25","author":"Rother","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jbc.2024.105784_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action","volume":"13","author":"Sheridan","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2024.105784_bib9","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","article-title":"Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"384","author":"Hillmen","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jbc.2024.105784_bib10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.tips.2022.01.004","article-title":"Compstatins: the dawn of clinical C3-targeted complement inhibition","volume":"43","author":"Lamers","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jbc.2024.105784_bib11","doi-asserted-by":"crossref","first-page":"29241","DOI":"10.1074\/jbc.M704587200","article-title":"Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition","volume":"282","author":"Janssen","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2024.105784_bib12","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1182\/blood-2008-11-189944","article-title":"Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab","volume":"113","author":"Risitano","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jbc.2024.105784_bib13","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3324\/haematol.2009.007229","article-title":"Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization","volume":"95","author":"Hill","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jbc.2024.105784_bib14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1423-0410.2011.01530.x","article-title":"Paroxysmal nocturnal haemoglobinuria treatment with eculizumab is associated with a positive direct antiglobulin test","volume":"102","author":"H\u00f6chsmann","year":"2012","journal-title":"Vox Sang."},{"key":"10.1016\/j.jbc.2024.105784_bib15","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1182\/blood-2014-12-616300","article-title":"Dissecting complement blockade for clinic use","volume":"125","author":"Risitano","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jbc.2024.105784_bib16","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/ajh.25016","article-title":"Toward complement inhibition 2.0: next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria","volume":"93","author":"Risitano","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jbc.2024.105784_bib17","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.3389\/fimmu.2019.01639","article-title":"Different levels of incomplete terminal pathway inhibition by eculizumab and the clinical response of PNH patients","volume":"10","author":"Harder","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jbc.2024.105784_bib18","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1182\/blood-2016-08-732800","article-title":"Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation","volume":"129","author":"Harder","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jbc.2024.105784_bib19","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood.2020005959","article-title":"Complement inhibition at the level of C3 or C5: mechanistic reasons for ongoing terminal pathway activity","volume":"137","author":"Mannes","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jbc.2024.105784_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720966137","article-title":"One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria na\u00efve to complement inhibitor therapy: open-label extension of a randomized study","volume":"11","author":"Schrezenmeier","year":"2020","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.jbc.2024.105784_bib21","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1182\/bloodadvances.2019031591","article-title":"Absence of complement component 3 does not prevent classical pathway-mediated hemolysis","volume":"3","author":"Zhang","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.jbc.2024.105784_bib22","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.1038\/s41467-021-25745-7","article-title":"C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates","volume":"12","author":"Schmitz","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2024.105784_bib23","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.3324\/haematol.2019.216028","article-title":"Complement C3 inhibition by compstatin Cp40 prevents intra- and extravascular hemolysis of red blood cells","volume":"105","author":"Baas","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jbc.2024.105784_bib24","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1034\/j.1399-3089.1999.00007.x","article-title":"Compstatin, a peptide inhibitor of C3, prolongs survival of ex\u00a0vivo perfused pig xenografts","volume":"6","author":"Fiane","year":"1999","journal-title":"Xenotransplantation"},{"key":"10.1016\/j.jbc.2024.105784_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/xen.12262","article-title":"Complement C3 inhibitor Cp40 attenuates xenoreactions in pig hearts perfused with human blood","volume":"24","author":"Abicht","year":"2017","journal-title":"Xenotransplantation"},{"key":"10.1016\/j.jbc.2024.105784_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo2341","article-title":"Complement C3 inhibition in severe COVID-19 using compstatin AMY-101","volume":"8","author":"Skendros","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jbc.2024.105784_bib27","doi-asserted-by":"crossref","first-page":"18552","DOI":"10.1074\/jbc.M611650200","article-title":"Structure-based mapping of DAF active site residues that accelerate the decay of C3 convertases","volume":"282","author":"Kuttner-Kondo","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2024.105784_bib28","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.15252\/embj.201593673","article-title":"Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode","volume":"35","author":"Forneris","year":"2016","journal-title":"EMBO J."},{"key":"10.1016\/j.jbc.2024.105784_bib29","doi-asserted-by":"crossref","first-page":"13273","DOI":"10.1016\/S0021-9258(17)36829-1","article-title":"Analysis of the functional domains of complement receptor type 1 (C3b\/C4b receptor; CD35) by substitution mutagenesis","volume":"269","author":"Krych","year":"1994","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2024.105784_bib30","doi-asserted-by":"crossref","first-page":"8623","DOI":"10.1074\/jbc.273.15.8623","article-title":"Structure-function analysis of the active sites of complement receptor type 1","volume":"273","author":"Krych","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2024.105784_bib31","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.4049\/jimmunol.156.7.2528","article-title":"Localization of classical and alternative pathway regulatory activity within the decay-accelerating factor","volume":"156","author":"Brodbeck","year":"1996","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jbc.2024.105784_bib32","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.4049\/jimmunol.1203548","article-title":"Rational engineering of a minimized immune inhibitor with unique triple-targeting properties","volume":"190","author":"Schmidt","year":"2013","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jbc.2024.105784_bib33","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nsmb.3427","article-title":"Regulator-dependent mechanisms of C3b processing by factor I allow differentiation of immune responses","volume":"24","author":"Xue","year":"2017","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.jbc.2024.105784_bib34","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.pep.2010.12.002","article-title":"Production of biologically active complement factor H in therapeutically useful quantities","volume":"76","author":"Schmidt","year":"2011","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.jbc.2024.105784_bib35","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.4049\/jimmunol.181.4.2610","article-title":"A\u00a0new map of glycosaminoglycan and C3b binding sites on factor H","volume":"181","author":"Schmidt","year":"2008","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jbc.2024.105784_bib36","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/imr.12475","article-title":"Protection of host cells by complement regulators","volume":"274","author":"Schmidt","year":"2016","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jbc.2024.105784_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0034820","article-title":"Lack of evidence from studies of soluble protein fragments that Knops blood group polymorphisms in complement receptor-type 1 are driven by malaria","volume":"7","author":"Tetteh-Quarcoo","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2024.105784_bib38","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nsmb.2018","article-title":"Structural basis for engagement by complement factor H of C3b on a self surface","volume":"18","author":"Morgan","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.jbc.2024.105784_bib39","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1074\/jbc.M410179200","article-title":"Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55)","volume":"280","author":"Harris","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2024.105784_bib40","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4049\/jimmunol.178.1.352","article-title":"Decay-accelerating factor must bind both components of the complement alternative pathway C3 convertase to mediate efficient decay","volume":"178","author":"Harris","year":"2007","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.jbc.2024.105784_bib41","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2017-05-781450","article-title":"Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults","volume":"130","author":"Konar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jbc.2024.105784_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.747594","article-title":"Alternative complement pathway inhibition does not Abrogate Meningococcal killing by serum of vaccinated individuals","volume":"12","author":"Ispasanie","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jbc.2024.105784_bib43","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.imbio.2015.12.009","article-title":"Selectivity of C3-opsonin targeted complement inhibitors: a distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients","volume":"221","author":"Schmidt","year":"2016","journal-title":"Immunobiology"},{"key":"10.1016\/j.jbc.2024.105784_bib44","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1128\/IAI.00321-12","article-title":"Prc contributes to Escherichia coli evasion of classical complement-mediated serum killing","volume":"80","author":"Wang","year":"2012","journal-title":"Infect. Immun."},{"key":"10.1016\/j.jbc.2024.105784_bib45","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/imr.13164","article-title":"Protein therapeutics and their lessons: expect the unexpected when inhibiting the multi-protein cascade of the complement system","volume":"313","author":"Schmidt","year":"2023","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jbc.2024.105784_bib46","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/ki.1988.214","article-title":"Metabolism of complement factor D in renal failure","volume":"34","author":"Pascual","year":"1988","journal-title":"Kidney Int."},{"key":"10.1016\/j.jbc.2024.105784_bib47","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/cei.12890","article-title":"Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders","volume":"187","author":"Wehling","year":"2017","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jbc.2024.105784_bib48","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/trf.12876","article-title":"Hyperhemolysis syndrome in a patient without a hemoglobinopathy, unresponsive to treatment with eculizumab","volume":"55","author":"Gupta","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.jbc.2024.105784_bib49","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jmb.2009.10.010","article-title":"The central portion of factor H (modules 10-15) is compact and contains a structurally deviant CCP module","volume":"395","author":"Schmidt","year":"2010","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.jbc.2024.105784_bib50","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/eci.12419","article-title":"Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention","volume":"45","author":"Mastellos","year":"2015","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.jbc.2024.105784_bib51","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2011-03-341305","article-title":"Plasmodium falciparum uses a key functional site in complement receptor type-1 for invasion of human erythrocytes","volume":"118","author":"Tham","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jbc.2024.105784_bib52","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1021\/acs.bioconjchem.6b00369","article-title":"PASylated coversin, a C5-specific complement inhibitor with extended pharmacokinetics, shows enhanced anti-hemolytic activity in\u00a0Vitro","volume":"27","author":"Kuhn","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jbc.2024.105784_bib53","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJM193712022172307","article-title":"Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria: study of the mechanism of hemolysis in relation to acid-Base equilibrium","volume":"217","author":"Ham","year":"1937","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.jbc.2024.105784_bib54","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood.V78.3.820.820","article-title":"Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum","volume":"78","author":"Wilcox","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.jbc.2024.105784_bib55","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.4049\/jimmunol.1801545","article-title":"Self versus Nonself Discrimination by the soluble complement regulators factor H and FHL-1","volume":"202","author":"Dopler","year":"2019","journal-title":"J.\u00a0Immunol."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925824001601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925824001601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:17:57Z","timestamp":1777414677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925824001601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0021925824001601"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2024.105784","relation":{},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triple-fusion protein (TriFu): A potent, targeted, enzyme-like inhibitor of all three complement activation pathways","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2024.105784","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"105784"}}